PAUL HARTMAN — Lobbyist Profile | Poliscope

PAUL HARTMAN

Reported covered position: 12/2015-1/2018-LA-Rep.Tim Murphy; 1/2018-1/2019-LA-Rep.Tom Garrett Jr.; 1/2019-3/2019-House Energy and Commerce Health Subcommittee; HHS Policy Advisor 3/2019-10/2019; 10/2019-8/2024-Policy Advisor Rep. Bob Latta

Filings

Clients

Firms

Years active

2024–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BIOMERIEUX	10	2024–2026

Lobbying firms

Firm	Filings	Years
BIOMERIEUX	10	2024–2026

Bills explicitly cited in this lobbyist’s assigned issues (8)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 2369

VALID Act of 2023

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

H.R. 2369

VALID Act of 2023

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

Original LDA source filings (10)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

BIOMERIEUX via BIOMERIEUX

2026 · third_quarter · Q3

Firm income: —Client expense: $150,000Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

TAR

Tariff (miscellaneous tariff bills)

Discussions regarding tariff proposals

MED

Medical/Disease Research/Clinical Labs

Discussions regarding PASTEUR Act, the RESULTS Act, CLIA Modernization, and antimicrobial resistance.

HCR

Health Issues

Source: Senate LDA

Show 4 more cited filings

H.R. 2940

PASTEUR Act

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

H.R. 2940

PASTEUR Act

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

H.R. 8078

Sepsis Harm and Cost Reduction Act

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

H.R. 8078

Sepsis Harm and Cost Reduction Act

Client: BIOMERIEUX · Firm: BIOMERIEUX

Open original LDA filing ↗

Cited source text

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

Show 6 more original filings

BIOMERIEUX via BIOMERIEUX

2025 · third_quarter · Q3

Firm income: —Client expense: $290,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

TAR

Tariff (miscellaneous tariff bills)

Discussions regarding tariff proposals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BIOMERIEUX via BIOMERIEUX

2025 · second_quarter · Q2

Firm income: —Client expense: $340,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

TAR

Tariff (miscellaneous tariff bills)

Discussions regarding tariff proposals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BIOMERIEUX via BIOMERIEUX

2025 · first_quarter · Q1

Firm income: —Client expense: $190,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

TAR

Tariff (miscellaneous tariff bills)

Discussions regarding tariff proposals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BIOMERIEUX via BIOMERIEUX

2024 · fourth_quarter · Q4

Firm income: —Client expense: $190,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BIOMERIEUX via BIOMERIEUX

2024 · third_quarter · Q3

Firm income: —Client expense: $200,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BIOMERIEUX via BIOMERIEUX

2024 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TAX

Taxation/Internal Revenue Code

Legislative and regulatory issues surrounding the medical diagnostics industry

HCR

Health Issues

Legislative and regulatory issues surrounding the medical diagnostics industry

TRD

Trade (domestic/foreign)

Legislative and regulatory issues surrounding the medical diagnostics industry